Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Apellis Pharmaceuticals / Equity Bottom-Up

<ul>
  <li>Apellis is a commercial-stage biopharmaceutical company with a first-in-class C3 inhibitor platform, having successfully launched two products: SYFOVRE for Geographic Atrophy (GA) and EMPAVELI for Paroxysmal Nocturnal Hemoglobinuria (PNH).</li>
  <li>The company is experiencing a significant revenue ramp, driven by the strong uptake of SYFOVRE, the first-ever approved treatment for GA, addressing a large and underserved market. This has shifted the company's financial profile towards profitability.</li>
  <li>Key risks center on the commercial execution and long-term safety profile of SYFOVRE, particularly concerning rare instances of retinal vasculitis, and intense competition in both the GA and PNH markets from established and emerging players.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Apellis is a commercial-stage biopharmaceutical company with a first-in-class C3 inhibitor platform, having successfully launched two products: SYFOVRE for Geographic Atrophy (GA) and EMPAVELI for Paroxysmal Nocturnal Hemoglobinuria (PNH).
  The company is experiencing a significant revenue ramp, driven by the strong uptake of SYFOVRE, the first-ever approved treatment for GA, addressing a large and underserved market. This has shifted the company's financial profile towards profitability.
  Key risks center on the commercial execution and long-term safety profile of SYFOVRE, particularly concerning rare instances of retinal vasculitis, and intense competition in both the GA and PNH markets from established and emerging players.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Apellis Pharmaceuticals (APLS US) - Nov 2025

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on C3 targeting therapies, reported a mixed set of results for the first quarter of 2025.</li><li>The quarter was marked by both achievements and challenges across their product portfolio.</li><li>Key products include SYFOVRE for geographic atrophy (GA) and EMPAVELI, targeting rare nephrology indications like C3G and IC-MPGN, the latter advancing toward possible FDA approval with a PDUFA date set for July 28.</li></ul>

Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on C3 targeting therapies, reported a mixed set of results for the first quarter of 2025.The quarter was marked by both achievements and challenges across their product portfolio.Key products include SYFOVRE for geographic atrophy (GA) and EMPAVELI, targeting rare nephrology indications like C3G and IC-MPGN, the latter advancing toward possible FDA approval with a PDUFA date set for July 28.

Apellis Pharma is Betting Big on Global Expansion for SYFOVRE; What Lies Ahead?

<ul><li>Apellis Pharmaceuticals reported a strong performance for the year ending 2024 but noted some transient headwinds.</li><li>The company achieved significant revenue growth, particularly from its flagship product SYFOVRE, which is a treatment for geographic atrophy (GA).</li><li>SYFOVRE generated over $900 million in net sales and performed well in the U.S. market, capturing over 60% of the market share.</li></ul>

Apellis Pharmaceuticals reported a strong performance for the year ending 2024 but noted some transient headwinds.The company achieved significant revenue growth, particularly from its flagship product SYFOVRE, which is a treatment for geographic atrophy (GA).SYFOVRE generated over $900 million in net sales and performed well in the U.S. market, capturing over 60% of the market share.

Apellis Pharmaceuticals’ Combination Therapy Approach With APL-3007 & SYFOVRE Might Just Pay Off!

<ul><li>Apellis Pharmaceuticals reported its third-quarter 2024 financial results, highlighting key developments and offering insights into future expectations.</li><li>The company, co-founded and led by CEO Dr. Cedric Francois, focuses on targeting C3 to address complement-mediated diseases.</li><li>During the third quarter, Apellis saw progress in commercial demand for SYFOVRE, although net product revenue for SYFOVRE dipped slightly by 1.7% due to factors like higher gross-to-net adjustments and contracting dynamics.</li></ul>

Apellis Pharmaceuticals reported its third-quarter 2024 financial results, highlighting key developments and offering insights into future expectations.The company, co-founded and led by CEO Dr. Cedric Francois, focuses on targeting C3 to address complement-mediated diseases.During the third quarter, Apellis saw progress in commercial demand for SYFOVRE, although net product revenue for SYFOVRE dipped slightly by 1.7% due to factors like higher gross-to-net adjustments and contracting dynamics.

Apellis Pharmaceuticals: Ophthalmology Field Team Expansion As A Critical Growth Lever! - Major Drivers

<ul><li>Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second quarter of 2024, presenting the progress and results for the period.</li><li>The management, specifically Chief Executive Officer Dr. Cedric Francois discussed the company's position with its products SYFOVRE and EMPAVELI, emphasizing SYFOVRE's leading market position in the treatment of geographic atrophy (GA), despite facing competitive pressures.</li><li>The company expressed optimism about SYFOVRE's robust performance in the market.</li></ul>

Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second quarter of 2024, presenting the progress and results for the period.The management, specifically Chief Executive Officer Dr. Cedric Francois discussed the company's position with its products SYFOVRE and EMPAVELI, emphasizing SYFOVRE's leading market position in the treatment of geographic atrophy (GA), despite facing competitive pressures.The company expressed optimism about SYFOVRE's robust performance in the market.

Apellis Pharmaceuticals Inc.: Market Leadership & Differentiation of SYFOVRE Driving Our Bullishness! - Major Drivers

United States

Apellis Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Apellis Pharmaceuticals serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Apellis Pharmaceuticals (APLS US)

Primer: Apellis Pharmaceuticals (APLS US) - Nov 2025

Apellis is a commercial-stage biopharmaceutical company with a first-in-class C3 inhibitor platform, having successfully launched two products:...

αSK

Apellis Pharma is Betting Big on Global Expansion for SYFOVRE; What Lies Ahead?

Apellis Pharmaceuticals, Inc., a biopharmaceutical company focused on C3 targeting therapies, reported a mixed set of results for the first...

Baptista Research

Apellis Pharmaceuticals’ Combination Therapy Approach With APL-3007 & SYFOVRE Might Just Pay Off!

Apellis Pharmaceuticals reported a strong performance for the year ending 2024 but noted some transient headwinds. The company achieved...

Baptista Research

Apellis Pharmaceuticals: Ophthalmology Field Team Expansion As A Critical Growth Lever! - Major Drivers

Apellis Pharmaceuticals reported its third-quarter 2024 financial results, highlighting key developments and offering insights into future...

Baptista Research

Apellis Pharmaceuticals Inc.: Market Leadership & Differentiation of SYFOVRE Driving Our Bullishness! - Major Drivers

Apellis Pharmaceuticals, a biopharmaceutical company, recently reported its earnings for the second quarter of 2024, presenting the progress and...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)